Growth Hormone Secretagogues

Tesamorelin

Egrifta (branded) · GHRH analogue

An FDA-approved GHRH analogue that increases endogenous growth hormone and IGF-1, used for HIV-associated lipodystrophy.

Overview & Mechanism

A stabilized analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary to secrete endogenous, pulsatile growth hormone, raising IGF-1.

Research Dosage

Dose

2 mg/day

Route

Subcutaneous injection

Frequency

Once daily

Cycle

6+ months

Reconstitution & Storage

Reconstitution

Reconstitute per kit instructions with provided diluent. Best administered in the evening.

Storage

Lyophilized: refrigerate 2–8 °C. Reconstituted: use per manufacturer (typically within 24 hours or refrigerated per label).

Safety & Side Effects

Injection-site reactions common. May cause joint pain, flushing, or edema. Monitor IGF-1.

Studies

Tesamorelin for HIV lipodystrophy

Tesamorelin 2 mg/day significantly reduced visceral adipose tissue and improved triglycerides in HIV patients with lipodystrophy over 26 weeks.

Read study

References

Research Use Only

This information is intended for licensed researchers and educational purposes only. It does not constitute medical advice. PureLife Health products are not approved for human use by Health Canada or the FDA. Always consult a qualified medical professional and verify against current literature.